Highest-materiality recent filing
Viskase posts $65.5M net loss in 2025; auditor flags going concern doubt
Net loss attributable to Viskase of $65.5M in 2025 vs loss of $5.4M in 2024; EPS of ($0.49).
Viskase extends credit maturity to Aug 2027, raises interest rates 100bps
Maturity of credit facility extended from Aug 13, 2026 to Aug 13, 2027.
Enzon completes all-stock merger with Viskase; combined company renamed Viskase Holdings
Enzon shareholders own ~45%, Viskase shareholders ~55% of combined company.
Enzon extends Series C Preferred exchange offer to Mar 9; rights plan extended to Mar 11
Exchange offer for Series C Preferred Stock extended to 11:59 p.m. ET on March 9, 2026.
Enzon stockholders approve 1-for-100 reverse stock split and merger with Viskase
Reverse stock split (1:100) approved by 55.2% of outstanding shares; merger proposal approved by 57.1%.
Enzon amends Viskase merger: Viskase holders get 55% of combined co; reverse split 1-for-100
Viskase stockholders will own 55% of combined company post-merger (up from prior ratio); Enzon stockholders 45%.
Enzon and Viskase sign merger; Enzon shareholders to own ~2% of combined co
Enzon to acquire Viskase in all-stock reverse merger; combined company will be named "Viskase Holdings, Inc." and trade on OTCQX.
Enzon appoints Stephen T. Wills to board; forms special committee to evaluate Viskase proposal
Board increased to four; Stephen T. Wills appointed as director effective January 7, 2025.
On April 29, 2026, Peter K. Shea notified the Company of his decision to resign as a member of the Board of Directors (the "Board"), including from his service on the Company’s Audit Committee.
On April 30, 2026, the Company appointed each of Mr. Thomas D. Davis, the Company’s Chief Executive Officer, and Mr. Craig Pettit to serve as members of the Board to fill the vacancies created by the resignations of Messrs. Peter Shea and Read.
Also, on April 29, 2026, Randolph C. Read notified the Company of his decision to resign as a member of the Board.
On April 30, 2026, the Company appointed each of Mr. Thomas D. Davis, the Company’s Chief Executive Officer, and Mr. Craig Pettit to serve as members of the Board to fill the vacancies created by the resignations of Messrs. Peter Shea and Read.
On January 7, 2025, the Board of Directors (the “Board”) of Enzon Pharmaceuticals, Inc. (the “Company”) approved an increase in the number of directors on the Board to four and appointed Stephen T. Wills as a director, effective immediately.
Max materiality 0.90 · Median 0.40 · Most common event other_material